Anti-FXYD3 Polyclonal Antibody for IHC-P, ELISA - Q14802

Core Product Specifications and Parameters

Biological Background: FXYD3 Function and Localization

• FXYD3 is a FXYD domain-containing protein, also designated mammary tumor 8 kDa protein (Mat-8) or phospholemman-like.
• It associates with and modulates the sodium/potassium-transporting ATPase (NKA) which transports Na(+) out of the cell and K(+) into the cell. Related references: PMID:17077088
• It reduces glutathionylation of the NKA beta-1 subunit ATP1B1, thereby reversing inhibition of the pump. Related references: PMID:21454534
• When expressed in Xenopus oocytes, it induces a hyperpolarization-activated chloride current. Related references: PMID:7836447
• FXYD3 alters the apparent ion affinities of NKA: it decreases K+ affinity over a range of membrane potentials and increases Na+ affinity at slightly negative and positive membrane potentials.
• The protein localizes to the cell membrane and undergoes alternative splicing, yielding isoform 1 (predominantly in differentiated cells) and isoform 2 (mainly in undifferentiated cells).
• Proteomics identification and direct protein sequencing confirm its transmembrane topology and signal peptide.

Experimental Guidance and Technical Tips

• For IHC-P, consider optimizing antigen retrieval conditions and testing primary antibody dilutions starting at 1:50 to 1:200.
• In ELISA, validate reactivity using the recombinant immunogen or endogenous target in relevant human tissue or cell lysates.
• As a polyclonal antibody, batch-to-batch consistency should be verified and appropriate controls included to ensure reproducible results.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is your one-stop partner for IVD raw materials, providing this anti-FXYD3 polyclonal antibody alongside a broad portfolio of related ion channel and cancer biomarker reagents. We support diagnostic manufacturers and research laboratories with validated antibody pairs, bulk ancillary reagents, and custom sourcing for rare targets—streamlining your assay development from concept to clinic.